2nd Jun 2014 10:06
LONDON (Alliance News) - Oxford Pharmascience Group PLC said Monday that it had seen positive results from a pilot clinical study of its reduced gastric irritation ibuprofen product OXP001.
The proof of concept clinical study was to determine the extent of upper gastrointestinal irritation of a 400 miligram OXP001 tablet compared with a 400 miligram ibuprofen tablet.
The study showed that OP001 showed "significantly less" gastrointestinal irritation compared to Ibuprofen. The company said some minor optimisation work will be required on the product, but the results allow it to move with confidence to a phase III clinical trial.
Oxford Pharmascience said that the results of the test also validate its OXPzero platform technology, underpinning its confidence to continue developing other non-steriodal anti-inflammatory drugs.
Shares in Oxford Pharmascience were trading up 5.8% at 4.76 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group